A study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer - FLAME

Study identifier:D0818R00008

ClinicalTrials.gov identifier:NCT05775549

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

FLAME - First Line olAparib Maintenance bEyond BRCA An Observational Cohort Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy Beyond BRCA Mutant Status in Newly Diagnosed Advanced Ovarian Cancer

Medical condition

Advanced Ovarian cancer

Phase

Phase 4

Healthy volunteers

No

Study drug

-

Sex

Female

Actual Enrollment

24

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 10 Jul 2023
Primary Completion Date: 27 Oct 2023
Study Completion Date: 27 Oct 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Merck

Inclusion and exclusion criteria